Jianxin Pang

NMPA Key Laboratory For Research And Evaluation Of Drug Metabolism & Guangdong Provincial Key Laboratory Of New Drug Screening & Guangdong Hongkong Macao Joint Laboratory For New Drug Screening
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery.

Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery.

Journal: Biosensors & bioelectronics

Published: September 24, 2025

An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysis.

An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysis.

Journal: Biochemical pharmacology

Published: September 02, 2025

PXR activation ameliorates hyperuricemic nephropathy via NRF2 signaling.

PXR activation ameliorates hyperuricemic nephropathy via NRF2 signaling.

Journal: Pharmacological research

Published: June 28, 2025

Design, synthesis and biological evaluation of 2-[1-(pyridin-2-ylmethyl)-1H-pyrazole-3-carboxamido]benzoic acids as promising urate transporter 1 inhibitors with potential nephroprotective efficacy for the treatment of hyperuricemic nephropathy.

Design, synthesis and biological evaluation of 2-[1-(pyridin-2-ylmethyl)-1H-pyrazole-3-carboxamido]benzoic acids as promising urate transporter 1 inhibitors with potential nephroprotective efficacy for the treatment of hyperuricemic nephropathy.

Journal: European journal of medicinal chemistry

Published: January 05, 2025

Loss of Urat1 exacerbates APAP-induced liver injury in mice.

Loss of Urat1 exacerbates APAP-induced liver injury in mice.

Journal: Toxicology

Published: October 14, 2024

Isobavachin alleviates hyperuricemia-induced bone loss by GPR35-NLRP3 signal.

Isobavachin alleviates hyperuricemia-induced bone loss by GPR35-NLRP3 signal.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: August 23, 2024

Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization.

Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization.

Journal: Nature communications

Published: July 31, 2024

Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production.

Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production.

Journal: Chemico-biological interactions

Published: April 10, 2024

Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.

Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.

Journal: European journal of medicinal chemistry

Published: January 25, 2024

Protecting against ferroptosis in hyperuricemic nephropathy: The potential of ferrostatin-1 and its inhibitory effect on URAT1.

Protecting against ferroptosis in hyperuricemic nephropathy: The potential of ferrostatin-1 and its inhibitory effect on URAT1.

Journal: European journal of pharmacology

Published: October 27, 2023

Pharmacological evaluation of a novel skeleton compound isobavachin (4',7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity.

Pharmacological evaluation of a novel skeleton compound isobavachin (4',7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity.

Journal: Bioorganic chemistry

Published: December 18, 2022

Mechanism of anti-hyperuricemia of isobavachin based on network pharmacology and molecular docking.

Mechanism of anti-hyperuricemia of isobavachin based on network pharmacology and molecular docking.

Journal: Computers in biology and medicine

Published: December 15, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026